Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate changes in clinical outcomes, inflammatory cytokine levels, and tear osmolarity in the tears of patients with moderate to severe dry eye syndrome before and after the application of topical 1% methylprednisolone. Materials and Methods: Thirty-two patients with moderate to severe dry eye unresponsive to previous aqueous enhancement therapy were enrolled. Five patients were lost to follow up, and twenty-seven patients were eligible for analysis. Patients were instructed to apply topical 1% methylprednisolone four times per day, as well as to continue applying their current therapy of preservative-free 0.1% sodium hyaluronate four times per day. Corneal and conjunctival staining scores, tear film breakup time (TFBUT), Schirmer test, and tear osmolarity were assessed at baseline,4 weeks, and 8 weeks. Tear samples were collected at every visit for cytokine analysis. Results: Corneal and conjunctival staining scores and TFBUT showed significant improvement at 4 (p<0.001, <0.001, <0.001 respectively) and 8 (p<0.001, <0.001, <0.001 respectively) weeks. Tear osmolarity decreased significantly at 8 weeks (p=0.008). Interleukin (IL)-1β, IL-8, and monocyte chemoattractant protein-1 were significantly decreased at 8 weeks compared with those at baseline (p=0.041, 0.001, 0.008 respectively). Conclusion: Short-term treatment with topical 1% methylprednisolone not only improved clinical outcomes, but also decreased tear osmolarity and cytokine levels. By measuring the changes in cytokine levels and tear osmolarity, we could objectively evaluate the anti-inflammatory effects of topical methylprednisolone applied in the treatment of patients with moderate to severe dry eye syndrome.
Abstract
Purpose: To evaluate changes in clinical outcomes, inflammatory cytokine levels, and tear osmolarity in the tears of patients with moderate to severe dry eye syndrome before and after the application of topical 1% methylprednisolone. Materials and Methods: Thirty-two patients with moderate to severe dry eye unresponsive to previous aqueous enhancement therapy were enrolled. Five patients were lost to follow up, and twenty-seven patients were eligible for analysis. Patients were instructed to apply topical 1% methylprednisolone four times per day, as well as to continue applying their current therapy of preservative-free 0.1% sodium hyaluronate four times per day. Corneal and conjunctival staining scores, tear film breakup time (TFBUT), Schirmer test, and tear osmolarity were assessed at baseline,4 weeks, and 8 weeks. Tear samples were collected at every visit for cytokine analysis. Results: Corneal and conjunctival staining scores and TFBUT showed significant improvement at 4 (p<0.001, <0.001, <0.001 respectively) and 8 (p<0.001, <0.001, <0.001 respectively) weeks. Tear osmolarity decreased significantly at 8 weeks (p=0.008). Interleukin (IL)-1β, IL-8, and monocyte chemoattractant protein-1 were significantly decreased at 8 weeks compared with those at baseline (p=0.041, 0.001, 0.008 respectively). Conclusion: Short-term treatment with topical 1% methylprednisolone not only improved clinical outcomes, but also decreased tear osmolarity and cytokine levels. By measuring the changes in cytokine levels and tear osmolarity, we could objectively evaluate the anti-inflammatory effects of topical methylprednisolone applied in the treatment of patients with moderate to severe dry eye syndrome.
참고문헌 (24)
- Johnson ME, "Changes in the tear film and ocular surface from dry eye syndrome", Prog Retin Eye Res, 23, pp.449~474 (2004)
- Lemp MA, "Report of the National Eye Institute", Industry workshop on Clinical Trials in Dry Eyes, 1995, pp.21, 221~232
- "The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)", Ocul Surf, 5, pp.75~92 (2007)
- Massingale ML, "Analysis of inflammatory cytokines in the tears of dry eye patients", Cornea, 28, pp.1023~1027 (2009)
- Lam H, "Tear cytokine profiles in dysfunctional tear syndrome", Am J Ophthalmol, 147, pp.198~205 (2009)
- Yoon KC, "Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, 51(2), pp.643~650 (2010), ASSOC RESEARCH VISION OPHTHALMOLOGY INC
- Suzuki M, "Tear osmolarity as a biomarker for dry eye disease severity", Invest Ophthalmol Vis Sci, 51, pp.4557~4561 (2010)
- Sullivan BD, "An objective approach to dry eye disease severity", Invest Ophthalmol Vis Sci, 51, pp.6125~6130 (2010)
- Stern ME, "Conjunctival T-cell subpopulations in Sjögren’s and non-Sjögren’s patients with dry eye", Invest Ophthalmol Vis Sci, 43, pp.2609~2614 (2002)
- Marsh P, "Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome", Ophthalmology, 106, pp.811~816 (1999)
- Lee HK, "Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients", OPHTHALMOLOGY, 113, pp.198~205 (2006)
- Sall K, "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group", Ophthalmology, 107, pp.631~639 (2000)
- De Paiva CS, "Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye", Exp Eye Res, 83, pp.526~535 (2006)
- Byun YJ, "Efficacy of Combined 0.05% Cyclosporine and 1% Methylprednisolone Treatment for Chronic Dry Eye", CORNEA, 31(5), pp.509~513 (2012), LIPPINCOTT WILLIAMS WILKINS
- Tomlinson A, "Effectiveness of dry eye therapy under conditions of environmental stress", Curr Eye Res, 38, pp.229~236 (2013)
- Li DQ, "Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells", Invest Ophthalmol Vis Sci, 45, pp.4302~4311 (2004)
- Baudouin C, "The pathology of dry eye", Surv Ophthalmol, 45(Suppl 2), pp.S211~S220 (2001)
- 이경일, "Kawasaki Disease: Laboratory Findings and an Immunopathogenesis on the Premise of a “Protein Homeostasis System”", Yonsei Medical Journal, 53(2), pp.262~275 (2012), 연세대학교의과대학
- Farris RL, "Tear osmolarity--a new gold standard?", Adv Exp Med Biol, 350, pp.495~503 (1994)
- Liacini A, "Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes", Matrix Biol, 21, pp.251~262 (2002)
- Nguyen CQ, "IL17: potential therapeutic target in Sjögren’s syndrome using adenovirus-mediated gene transfer", Lab Invest, 91, pp.54~62 (2011)
- Lagu B, "Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma", Bioorg Med Chem Lett, 17, pp.4382~4386 (2007)
- Nichols JJ, "Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye", Invest Ophthalmol Vis Sci, 47, pp.1319~1328 (2006)
- Benelli U, "Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness", Cont Lens Anterior Eye, 33, pp.61~67 (2010)